ArticleERJ open research2019
Inflammatory biomarkers are associated with aetiology and predict outcomes in community-acquired pneumonia: results of a 5-year follow-up cohort study.
Article in ERJ open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Role of Inflammatory Markers as a Risk Factor for Community-Acquired Pneumonia Management.Medicina (Kaunas, Lithuania) · 2025Article
- Endothelial Biomarkers Are Superior to Classic Inflammatory Biomarkers in Community-Acquired Pneumonia.Biomedicines · 2024Article
- The assessment of pentraxin 3: a diagnostic and prognostic biomarker in lower respiratory tract infections in children.Italian journal of pediatrics · 2024Article
- Enhancing pneumonia prognosis in the emergency department: a novel machine learning approach using complete blood count and differential leukocyte count combined with CURB-65 score.BMC medical informatics and decision making · 2024Article
- Nausea Predicts Bacteremia in Immunocompetent Patients with Pneumococcal Community-Acquired Pneumonia: Secondary Data Analysis from a Prospective Cohort.Journal of clinical medicine · 2023Article
- Article
- Overruling of Procalcitonin-Guided Antibiotics for Lower Respiratory Tract Infections in Primary Care: Ancillary Study of a Randomized Controlled Trial.Antibiotics (Basel, Switzerland) · 2023Article
- C-Reactive Protein as a Predictor of Survival and Length of Hospital Stay in Community-Acquired Pneumonia.Journal of personalized medicine · 2022Article
- Diagnostic Accuracy of Procalcitonin upon Emergency Department Admission during SARS-CoV-2 Pandemic.Antibiotics (Basel, Switzerland) · 2022Article
- The Potential Use of Saliva as a Biofluid for Systemic Inflammatory Response Monitoring in Children with Pneumonia.Indian journal of pediatrics · 2022Article
- Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID-19.Journal of clinical laboratory analysis · 2021Article
- Biomarker Value in the Diagnosis of Community-Acquired Pneumonia with Concomitant Chronic Heart Failure.Journal of clinical medicine · 2021Article
- Calprotectin: An Ignored Biomarker of Neutrophilia in Pediatric Respiratory Diseases.Children (Basel, Switzerland) · 2021Review
- Hepcidin and Ferritin Predict Microbial Etiology in Community-Acquired Pneumonia.Open forum infectious diseases · 2021Article
- Neutrophil-Dependent Immunity During Pulmonary Infections and Inflammations.Frontiers in immunology · 2021Review
- Predicting 30-day mortality of patients with pneumonia in an emergency department setting using machine-learning models.Clinical and experimental emergency medicine · 2020Article
- Procalcitonin and C-reactive protein perform better than the neutrophil/lymphocyte count ratio in evaluating hospital acquired pneumonia.BMC pulmonary medicine · 2020Article
- Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac).Journal of clinical medicine · 2020Review
- [The new comprehension of pulmonary infections].Der Pneumologe · 2020Review
- Vitamin D Status in Neonatal Pulmonary Infections: Relationship to Inflammatory Indicators.Open access Macedonian journal of medical sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiomarkers may facilitate clinical decisions in order to guide antimicrobial treatment and prediction of prognosis in community-acquired pneumonia (CAP). We measured serum C-reactive protein, procalcitonin (PCT) and calprotectin levels, and plasma pentraxin 3 (PTX3) and presepsin levels, along with whole-blood white cell counts, at three time-points, and examined their association with microbial aetiology and adverse clinical outcomes in CAP.
methodsBlood samples were obtained at hospital admission, clinical stabilisation and 6-week follow-up from 267 hospitalised adults with CAP. Adverse short-term outcome was defined as intensive care unit admission and 30-day mortality. Long-term outcome was evaluated as 5-year all-cause mortality.
resultsPeak levels of all biomarkers were seen at hospital admission. Increased admission levels of C-reactive protein, PCT and calprotectin were associated with bacterial aetiology of CAP, while increased admission levels of PCT, PTX3 and presepsin were associated with adverse short-term outcome. In univariate and multivariate regression models, white blood cells and calprotectin at 6-week follow-up were predictors of 5-year all-cause mortality.
conclusionsCalprotectin emerges as both a potential early marker of bacterial aetiology and a predictor for 5-year all-cause mortality in CAP, whereas PCT, PTX3 and presepsin may predict short-term outcome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.